Vivo Capital IX, LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 5:48 pm Sale |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
Vivo Capital IX, LLC | 3,761,947 3.100% |
-5,647,104 (-60.02%) |
Filing |
| 2022-02-11 5:26 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
Vivo Capital IX, LLC | 9,409,051 7.800% |
448,755 (+5.01%) |
Filing |
| 2021-02-16 4:30 pm Sale |
2020-12-31 | 13G | Mereo BioPharma Group plc MREO |
Vivo Capital IX, LLC | 8,960,296 8.168% |
-21,635,328 (-70.71%) |
Filing |
| 2020-07-10 4:30 pm Purchase |
2020-06-30 | 13G | Mereo BioPharma Group plc MREO |
Vivo Capital IX, LLC | 30,595,624 9.000% |
16,480,873 (+116.76%) |
Filing |
| 2020-06-12 5:00 pm Purchase |
2020-06-04 | 13G | Mereo BioPharma Group plc MREO |
Vivo Capital IX, LLC | 14,114,751 6.600% |
14,114,751 (New Position) |
Filing |